JP7671253B2 - 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体 - Google Patents

強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体 Download PDF

Info

Publication number
JP7671253B2
JP7671253B2 JP2021553296A JP2021553296A JP7671253B2 JP 7671253 B2 JP7671253 B2 JP 7671253B2 JP 2021553296 A JP2021553296 A JP 2021553296A JP 2021553296 A JP2021553296 A JP 2021553296A JP 7671253 B2 JP7671253 B2 JP 7671253B2
Authority
JP
Japan
Prior art keywords
hsv
cancer
cell
seq
naturally occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524379A5 (https=
JP2022524379A (ja
JPWO2020186238A5 (https=
Inventor
ティモシー ピー． クライプ，
ケヴィン エー． キャサディ，
ピン－イー ワン，
ジュリア ケー． ハーリー，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2022524379A publication Critical patent/JP2022524379A/ja
Publication of JP2022524379A5 publication Critical patent/JP2022524379A5/ja
Publication of JPWO2020186238A5 publication Critical patent/JPWO2020186238A5/ja
Priority to JP2024218272A priority Critical patent/JP2025028186A/ja
Application granted granted Critical
Publication of JP7671253B2 publication Critical patent/JP7671253B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C12N15/8695—Herpes simplex virus-based vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00051—Methods of production or purification of viral material
    • C12N2710/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021553296A 2019-03-14 2020-03-13 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体 Active JP7671253B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218272A JP2025028186A (ja) 2019-03-14 2024-12-12 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962818577P 2019-03-14 2019-03-14
US62/818,577 2019-03-14
US201962932725P 2019-11-08 2019-11-08
US62/932,725 2019-11-08
PCT/US2020/022806 WO2020186238A1 (en) 2019-03-14 2020-03-13 Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218272A Division JP2025028186A (ja) 2019-03-14 2024-12-12 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体

Publications (4)

Publication Number Publication Date
JP2022524379A JP2022524379A (ja) 2022-05-02
JP2022524379A5 JP2022524379A5 (https=) 2023-03-20
JPWO2020186238A5 JPWO2020186238A5 (https=) 2023-03-20
JP7671253B2 true JP7671253B2 (ja) 2025-05-01

Family

ID=72426047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553296A Active JP7671253B2 (ja) 2019-03-14 2020-03-13 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体
JP2024218272A Pending JP2025028186A (ja) 2019-03-14 2024-12-12 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218272A Pending JP2025028186A (ja) 2019-03-14 2024-12-12 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体

Country Status (11)

Country Link
US (1) US12480097B2 (https=)
EP (1) EP3937960A4 (https=)
JP (2) JP7671253B2 (https=)
KR (1) KR102933002B1 (https=)
CN (1) CN113710259B (https=)
AU (1) AU2020235140B2 (https=)
BR (1) BR112021017651A2 (https=)
CA (1) CA3132867A1 (https=)
IL (1) IL286142B2 (https=)
SG (1) SG11202109707VA (https=)
WO (1) WO2020186238A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120380154A (zh) * 2022-12-14 2025-07-25 Eg427公司 改良型单纯疱疹病毒1型

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505103A (ja) 1999-08-03 2003-02-12 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 組換えｈｓｖ−１および生ウイルスワクチン
WO2005005637A2 (en) 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5639361B2 (ja) * 2006-09-08 2014-12-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｓｖ−１及びｈｓｖ−２ワクチン並びにその使用方法
JP6726824B2 (ja) * 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
JP6865736B2 (ja) * 2015-05-04 2021-04-28 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 腫瘍溶解性ｈｓｖ１ベクターおよび使用法
US10596234B2 (en) 2016-10-28 2020-03-24 University Of Southern California Compositions and methods to inhibit viral replication
JP7490365B2 (ja) * 2017-03-09 2024-05-27 シァメン・ユニヴァーシティ 組み換え単純ヘルペスウイルス及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505103A (ja) 1999-08-03 2003-02-12 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 組換えｈｓｖ−１および生ウイルスワクチン
WO2005005637A2 (en) 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d

Also Published As

Publication number Publication date
AU2020235140A1 (en) 2021-09-30
JP2025028186A (ja) 2025-02-28
CN113710259A (zh) 2021-11-26
KR102933002B1 (ko) 2026-03-04
CN113710259B (zh) 2024-12-31
JP2022524379A (ja) 2022-05-02
IL286142B2 (en) 2026-03-01
EP3937960A4 (en) 2023-03-29
IL286142B1 (en) 2025-11-01
EP3937960A1 (en) 2022-01-19
SG11202109707VA (en) 2021-10-28
KR20210139306A (ko) 2021-11-22
CA3132867A1 (en) 2020-09-17
WO2020186238A1 (en) 2020-09-17
AU2020235140B2 (en) 2026-03-26
BR112021017651A2 (pt) 2021-11-16
US12480097B2 (en) 2025-11-25
US20220154149A1 (en) 2022-05-19
IL286142A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CN110128550B (zh) 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
CN114174520B (zh) 用于选择性基因调节的组合物和方法
Costes et al. Cloning of the koi herpesvirus genome as an infectious bacterial artificial chromosome demonstrates that disruption of the thymidine kinase locus induces partial attenuation in Cyprinus carpio koi
Berges et al. Transduction of brain by herpes simplex virus vectors
JP2020528734A (ja) バリアントカプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
JP2020536510A (ja) 細胞の遺伝子修飾のための非組込みｄｎａベクター
CN109362223A (zh) 高转导hsv载体
US10806761B2 (en) Oncolytic HSV1 vector and methods of use
CN103074305B (zh) 重组水痘-带状疱疹病毒
Chen et al. Construction of a full-length infectious bacterial artificial chromosome clone of duck enteritis virus vaccine strain
JP2025028186A (ja) 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体
Qi et al. Establishment of a fosmid library for pseudorabies virus SC strain and application in viral neuronal tracing
JP4551042B2 (ja) ヘルペスγ３４．５遺伝子発現の細胞特異的および／または腫瘍特異的プロモーター再標的化
EP2460878B1 (en) Orf7 deficient varicella virus, vaccine comprising the virus and use thereof
CN1509764A (zh) 一种抗癌靶向基因病毒药物的制备方法
RU2821999C2 (ru) Синцитиальные онколитические мутанты herpes simplex в качестве мощных терапевтических средств для лечения рака
US20250263741A1 (en) Hsv vectors
Grant et al. Engineering cell lines for production of replication defective HSV‐1 gene therapy vectors
JP2023552535A (ja) 異種導入遺伝子の発現を制御するためのオーファンモチーフ（ｏｒｐｈａｎ ｍｏｔｉｆ）とＣｐＧ密度との組み合わせの使用
CN110564700B (zh) 携带鲎凝集素基因的溶瘤痘苗病毒、构建方法及应用
WO1999036559A1 (en) Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use
HK40063431A (en) Oncolytic hsv1 vector and methods of use
CN118389455A (zh) 一种表达荧光素酶和荧光蛋白的重组猫疱疹病毒的制备和应用
That Cloning of the Koi Herpesvirus Genome as
Li Biochemical Studies on Avian and Human Adenoviruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250418

R150 Certificate of patent or registration of utility model

Ref document number: 7671253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150